Tag: big pharma

Meet the Latest Vaccine Propagandist

On January 05, 2024, this Pharma Propaganda outlet published a video interview with Dr. Paul Offit, professional academic pediatrician and vaccine shill, in which he states a series of falsehoods in continuation of the gaslighting and falsehoods which both he and Dr. Peter Marks (FDA/CBER) are becoming known for.

Lets take a look at the transcript of this series of falsehoods.

First off, starting with the title, is Paul Offit actually a vaccine expert? What have his contributions actually been? Well, he self-identifies as the co-inventor of a licensed rotavirus vaccine (one of many, and not the first), and has received significant royalties from that. I should say currently licensed rotavirus vaccine, because there was a prior rotavirus vaccine (RotaShield – Wyeth) which was associated with an intolerable level of a clinical syndrome called “intussusception.”

If you know horses, you can think of intussusception as sort of like colic, but most often happening in children. More precisely, intussusception is a condition in which one segment of intestine “telescopes” inside of another, causing an intestinal obstruction (blockage). For some reason, rotavirus vaccines are associated with intussusception. It can be life threatening. The previously licensed rotavirus vaccine had a slightly higher rate of intussusception than the current one associated with Dr. Paul Offit (and Dr. H. Fred Clark, the senior of the two researchers).

This essay details the events surrounding the RotaShield withdrawal, including the role of Offit when participating in the Advisory Committee on Immunization Practices at the CDC. Basically, all US children are required to take either Offit’s vaccine or a competing similar live attenuated virus product. According to the CDC:

There is also a small risk of intussusception from rotavirus vaccination, usually within a week after the first or second dose. This additional risk is estimated to range from about 1 in 20,000 to 1 in 100,000 US infants who get rotavirus vaccine.

There are about 3.66 million births per year in the US, so that means between 36 to 180 cases of life-threatening intussusception in the US per year due to mandated administration of this product.

Keep reading

RFK Jr: “Pediatricians who vaccinate 80-85% of the kids in their office, get these GIANT bonuses!”

This is perhaps the most important — and most dangerous — article I have ever posted.

But I have to print the truth wherever I find it.

Let’s start with this clip from RFK Jr. explaining how pediatricians are given an incentive to vaccine your children with ALL the vaccines produced by Big Pharma…

So to summarize what he just said, he claims that pediatricians are given a monetary payout — a BONUS — if they vaccinate a high rate of children in their clinic.

He claims it can be as high as $400/child….

But ONLY IF they maintain high levels of vaccination overall at the clinic.

Which is why they freak out on you if you refuse to get the vaccines or don’t want to follow the CDC schedule.

It’s not hard to imagine in this scenario where they start to see each little kid with a dollar sign over their heads instead of a patient!

RFK Jr. explains how the business model is to increase traffic into the clinic.

Unlike when we were kids, and you only went to the doctor if you got hurt, now you go all the time!

Why?

“BUSINESS MODEL”.

Keep reading

Pharma-Friendly Public Health Officials Launch New Project to ‘Shore Up U.S. Vaccination Policy’

A group of public health figures has launched a new project they hope will “shore up U.S. vaccination policy,” which they believe is under threat from U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.

The “Vaccine Integrity Project,” launched Thursday, is funded by iAlumbra, a nonprofit founded by Walmart heiress and philanthropist Christy Walton. It will be based at the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP).

Michael Osterholm, Ph.D., CIDRAP director and a member of the COVID-19 Advisory Board under the Biden administration, said the project “acknowledges the unfortunate reality that the system that we’ve relied on to make vaccine recommendations and to review safety and effectiveness data faces threats.”

Former U.S. Food and Drug Administration (FDA) Commissioner Margaret Hamburg and Dr. Harvey Fineberg, former president of the Institute of Medicine and current president of the Gordon and Betty Moore Foundation, will co-chair an eight-member steering committee leading the initiative.

The group behind the project cited “a growing chorus of voices” in the U.S. questioning the safety and efficacy of vaccines as one of the inspirations for launching the project, Fierce Biotech reported.

In an op-ed published in STAT News, Hamburg and Fineberg said the project will use “the best available evidence” to “safeguard vaccine policy, information and utilization.”

The project will hold information-gathering sessions with public health stakeholders and share its recommendations with “nongovernment entities … that are free of outside influence and focus on protecting Americans from vaccine-preventable diseases.”

According to a press release, the project’s recommendations will be “grounded in the best available science.”

Keep reading

FDA Removing Pharmaceutical Representatives From Advisory Panels

The Food and Drug Administration (FDA) is removing pharmaceutical company representatives from advisory committees in a bid to limit industry influence.

Dr. Marty Makary, the FDA’s new commissioner, issued a directive that eliminates the role of pharmaceutical representative

“Industry employees are welcome to attend FDA advisory committee meetings, along with the rest of the American public, but having industry employees serve as official members of FDA advisory committee members represents a cozy relationship that is concerning to many Americans,” Makary said in a statement on April 17. “In fact, the FDA has a history of being influenced unduly by corporate interests.”

The FDA has 32 different advisory committees, including panels that advise the agency on vaccines, food, and medical devices. Members are primarily a mix of federal employees and experts who do not work for industries.

But each FDA committee has an industry representative and an alternate industry representative. The Vaccine and Related Biological Products Advisory Committee, for instance, had a Pfizer officer and a Dynavax officer listed on the roster for its most recent meeting.

The industry representatives do not vote on what advice to convey to the FDA, but “offer perspective of a pharmaceutical company,” Kim Witczak, who has served on several FDA advisory committees, told The Epoch Times in an email.

“Sometimes they will say something that could influence or sway the discussion. I always wondered why they were on the committee,” she said.

Keep reading

Mental Health “Experts” FEAR Secretary Kennedy’s Investigation into Psychiatric Drugging

Within a few weeks of Donald Trump’s inauguration, the President signed an Executive Order establishing the Make America Healthy Again Commission (MAHA), which, among other things, will be “assessing the prevalence of and threat posed by the prescription of Selective Serotonin Reuptake Inhibitors (SSRIs), antipsychotics, mood stabilizers, stimulants and weight-loss drugs.” In other words, officialdom finally is looking at the out-of-control unscientific chemical experimentation used to address unwanted behaviors.

Alert the media! Get Megyn Kelly on the phone! Finally, a governmental body will be looking into the serious risks associated with prescription mind-altering drugs. It’s decades in the making. But, as they say, “better late than never.” It was no surprise then that within a month of that announcement the mental health industry was none too pleased and released a “joint statement” about the wonders of its mind-altering chemical elixirs.

According to the statement, “these drugs provide relief for many young people enabling them to participate fully in treatment, school, social activities, and family life — all key aspects of healthy development.” Utter nonsense.

“Healthy development?” There is no such thing as the decades-long touted “chemical imbalance.” That theory finally got debunked in 2022 research published by Professor Joanna Moncrieff and Dr. Mark Horowitz. So, since it’s clear that people are not “short” on certain brain chemicals as a reason for depression, then why are those chemicals being prescribed as “treatment?” And, make no mistake, lots and lots of Americans are being drugged.

According to data gathered in 2020 by IQVIA (Formerly IMS Health) and made public by the Citizens Commission on Human Rights (CCHR) in January of 2021, nearly 77 million Americans are taking at least one prescription psychiatric drug. The breakdown of who is drugged is jaw dropping crazy. There were more than 85 thousand 0–1-year-olds, nearly 140,000 2–3-year-olds, 215,000 4- to five-year-olds, two-and-a-half million 6–12-year-olds and more than three million 13–17-year-olds taking psychiatric mind-altering drugs every day.

Keep reading

Fired FDA Chief Is Now Out Trashing RFK Jr. and his Autism Study on the Fake News – Big Pharma Has Most to Lose

Dr. Peter Marks, the FDA’s top vaccine official and a key figure in the first Trump administration’s Operation Warp Speed, was ousted from his post earlier this month.

​Dr. Peter Marks is an American hematologist-oncologist who has served as the director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) since 2016.

As CBER director, Marks was responsible for reviewing and providing advice during product development, evaluating applications, and making approval decisions based on safety and effectiveness data.

He oversaw the FDA’s vaccine programs and played a pivotal part in the rapid development and approval of the experimental COVID-19 vaccines under Operation Warp Speed during President Donald Trump’s first term.

Sources close to the matter told the Wall Street Journal that Marks submitted his resignation on Friday after a blunt ultimatum from a Health and Human Services (HHS) official: step down voluntarily or face termination.

His exit, effective April 5, marks yet another victory for HHS Secretary Robert F. Kennedy Jr.’s aggressive push to purge the federal health apparatus of what he calls entrenched bureaucrats peddling “misinformation and lies.”

It was very telling that Big Pharma stocks plunged following his resignation.

Shares of vaccine makers Moderna and Novavax, along with several other biotech companies, plunged following his resignation.

Now, Marks is out hitting the Sunday shows and attacking Robert Kennedy Jr.  It makes you wonder who is behind this?

The Disgraced former FDA official is ALREADY defending Big Pharma from RFK Jr’s groundbreaking study on autism.

This is how committed the Big Money players are with keeping the vaccines flowing no matter how many Americans will be injured or killed.

Keep reading

Trump Admin Launches National Security Probe Into Pharma, Semiconductor Imports

The Trump administration has launched an investigation into the effects on national security of importing semiconductors and pharmaceutical products, according to Federal Register filings on Monday.

The Commerce Department, in a pair of Federal Register notices set to be published on April 16, said that the probes were initiated under Section 232 of the Trade Expansion Act—which allows the president to impose tariffs on imports considered a threat to national security.

The department stated that it began investigating the national security implications of importing semiconductors and semiconductor manufacturing equipment (SME) on April 1.

This includes “semiconductor substrates and bare wafers, legacy chips, leading-edge chips, microelectronics, and SME components,” as well as derivative products of those items, according to one of the filings.

The probe will assess current and projected demand for semiconductors and SME in the United States; the extent to which domestic production can or is expected to meet that demand; the role of foreign fabrication and assembly; the concentration of U.S. semiconductor imports; and the potential for export restrictions by other nations; among other issues.

In another notice, the department said it was investigating imports of pharmaceuticals and their ingredients. This includes “finished generic and non-generic drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients and key starting materials, and derivative products of those items.”

Keep reading

FDA Says It Plans to Phase out Animal Testing for Drug Development

The Food and Drug Administration (FDA) on April 10 said it will be phasing out animal testing for monoclonal antibodies and other drugs.

FDA officials said that its animal testing requirement will be “reduced, refined, or potentially replaced” with other approaches, including advanced computer simulations utilizing artificial intelligence and lab-grown products that are designed to mimic human organs.

The agency will also start looking at preexisting, real-world safety data from other countries that have regulatory standards similar to those in the United States.

“For too long, drug manufacturers have performed additional animal testing of drugs that have data in broad human use internationally. This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,” FDA Commissioner Dr. Marty Makary said in a statement.

He said that the move “represents a major step toward ending the use of laboratory animals in drug testing.”

Companies that submit what the agency described as strong safety data from non-animal testing could receive faster review, according to the FDA.

Keep reading

Swiss Pharma Company Announces $23 Billion U.S. Investment Days After Trump Pledged ‘Major Tariff’ on Drug Imports

Pharmaceutical company Novartis announced plans to build seven facilities in the United States and expand others in a $23 billion investment over five years on the heels of President Donald Trump’s announcement of forthcoming tariffs on imported drugs.

The Swiss company revealed the major investment in a press release.

“This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country with 10 facilities, including 7 brand new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional US jobs,” the release said.

Six of the facilities will be manufacturing plants, two of which will focus on radioligand therapy in Florida and Texas. It remains to be seen where the other four plants will be built.

Moreover, the company is establishing a biomedical research innovation center in San Diego as part of the investment, and it is expanding three of its production facilities in Indiana, New Jersey, and California.

The company also noted that its goal is to ensure “all key Novartis medicines for US patients will be made in the United States.”

Keep reading

Profits Over Patients: How Big Pharma Weaves Its Web Of Corruption And Drug Dependency

 I never set out to be an advocate. I wasn’t a doctor, scientist, or policy expert. I was just a regular person who, like so many, blindly trusted that our healthcare system was designed to protect us.

But life has a way of pulling us into the arena when we least expect it.

After the tragic and unexpected loss of my husband Woody to the antidepressant Zoloft he was prescribed for insomnia, I was thrust into a world I never imagined—one where medicine wasn’t solely about healing, but deeply entangled in a system that prioritizes profit over safety, buries harms, and keeps the public in the dark.

For over two decades, I’ve had a front-row seat to how this system truly operates—not the illusion of rigorous oversight we see in medical journals or glossy pharmaceutical ads, but the reality of how industry influence is woven into every stage.

I’ve met with regulators, testified before the FDA and Congress, filed a wrongful death and failure-to-warn lawsuit against Pfizer, and earned a seat on the FDA’s Psychopharmacologic Drugs Advisory Committee as a consumer representative.

I’ve also spoken at and participated in global conferences like Selling Sickness, Too Much Medicine, and the Harms in Medicine meeting in Erice, Italy—where some of the world’s leading experts acknowledge what few in mainstream medicine dare to say:

Our healthcare system isn’t about health—it’s about business.

And in this business, harm isn’t an accident. It’s built into the system.

The more I uncovered, the more I realized:

We aren’t just patients. We are customers.

And we are all trapped in Big Pharma’s spiderweb of influence.

Keep reading